Exagen (XGN)

• Market cap: $63.1M
• 1 day: -5.29%
• 5 days: -17.51%
• 1 month: -10.72%
• 3 months: -8.67%
• 6 months: 16.61%
• Year to date: 15.86%
• 1 year: 77.23%
• 5 years: -79.91%
• 10 years: -80.73%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 179

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

25% more capital invested

Capital invested by funds: $19.8M [Q3] → $24.8M (+$5.01M) [Q4]

18% more funds holding

Funds holding: 34 [Q3] → 40 (+6) [Q4]

2.52% less ownership

Funds ownership: 36.77% [Q3] → 34.25% (-2.52%) [Q4]

43% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 14

81% less call options, than puts

Call options by funds: $5K | Put options by funds: $26K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 96% upside
• Avg. target: $7.50 109% upside
• High target: $8 123% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 59% 1-year accuracy 27 / 46 met price target	123% upside $8	Overweight Reiterated	13 Jan 2025
Canaccord Genuity Kyle Mikson 46% 1-year accuracy 13 / 28 met price target	96% upside $7	Buy Maintained	3 Jan 2025